217eP Immunotherapy beyond trials: Dostarlimab in advanced endometrial cancer: A Portuguese multicenter experience

20250 citationsJournal Articlegold Open Access

Authors

M.Q. Pereira

P. Antunes Meireles

I. Miguel · Instituto Português de Oncologia de Coimbra Francisco Gentil

A.R.D.S. Lopes · IPO Porto

JMC Rodrigues · Hospitais da Universidade de Coimbra

M.C. Couto · Hospital de São João

I.C. Gomes Fernandes · Centro De Medicina Veterinária Anjos De Assis

M.T. Crisóstomo

Abstract

Dostarlimab was available in Portugal for advanced or recurrent endometrial cancer post–platinum therapy via early access(EAP) since November 2021, with reimbursement from October 2024; its use with carboplatin and paclitaxel was authorized under EAP in June 2024. Until now, no national real-world data have been reported.

Topics & Keywords

Endometrial and Cervical Cancer Treatments Reproductive System and Pregnancy Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Immuno-Oncology Technology

Volume 28, pp. 101300-101300

DOI: 10.1016/j.iotech.2025.101300

Field-Weighted Citation Impact: 0.00